Market Overview

Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017

Share:





Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the
"Company") a clinical stage biopharmaceutical company focused on the
global immunology market, presented new duration of remission data from
its global Phase IIB AURA-LV (AURA) study in lupus nephritis (LN) during
the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid,
Spain. The presentation was made during the late-breaking session by
Prof. Vladimir A. Dobronravov, MD, PhD, DSc, a clinical investigator for
the study and Vice Director, Research Institute of Nephrology, 1st
St-Petersburg Pavlov State Medical University.

As previously reported, treatment with low dose voclosporin showed
statistically improved efficacy over the control arm at both 24 and 48
weeks, with a doubling of remission rates at 48 weeks versus the control
arm (49% vs 24%). These results were achieved in the presence of low
doses of corticosteroids and normal, stable renal function. Furthermore,
of the low-dose voclosporin patients that achieved CR at 24 weeks, 100%
remained in CR at 48 weeks, establishing durability of clinical
response. The data presented at EULAR 2017 demonstrated that over the
course of the 48-week trial, patients on voclosporin stayed in remission
approximately twice the amount of time as those in the control group.
These differences were statistically significant versus the control arm.
Duration of remission as measured by proteinuria is clinically
meaningful as it may correlate with lower rates of progression to
Chronic Kidney Disease.1

The remission results at 48 weeks are summarized below.

Treatment Group       Complete Remission      

Duration of Remission through
48 weeks (mean days,
95%CI)

(measured by UPCR ≤.5mg/mg)

VCS 23.7mg BID       49%       123 (96.1,148.4)
      p<.001       p=.0012
VCS 39.5mg BID       40%       111 (82.7,129.7)
      p=.026       p=.01
Control Group       24%       66 (43.0,88.5)
      NA       NA
           

"Not only have more patients on voclosporin achieved complete remission,
but they have done so faster. Patients on low-dose voclosporin are also
maintaining remission for a longer duration—nearly twice that of the
control group on average," stated Dr. Dobronravov. "The quicker we can
bring patients into remission and keep them there, the more likely we
are to delay or even prevent the deleterious effects of prolonged
inflammation which can lead to irreversible kidney damage."

All arms of the study included the current standard of care of
mycophenolate mofetil (MMF) as background therapy and an aggressive
steroid taper. Both doses of voclosporin at 48 weeks demonstrated
continued improvement over the control group across multiple measures.
The voclosporin treated groups demonstrated statistically significant
improvement over the control group in speed and rates of complete and
partial remission (CR and PR, respectively). Proteinuria levels and
reduction in Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) scores, which include non-renal measures of lupus activity,
also continued to significantly improve over time versus the control
group. Additional analyses are ongoing and will be presented at future
medical and scientific meetings.

No unexpected safety signals nor adverse events were observed and
voclosporin was generally well-tolerated, consistent with what is
expected of patients suffering from active LN while undergoing
immunomodulation-based therapy. In the voclosporin arms, renal function
as measured by estimated glomerular filtration rate (eGFR) was stable
and not significantly different from the control arm following the
48-week treatment period. There were no electrolyte changes in the
treatment groups and mean blood pressure was also similar across
treatment groups through 48 weeks.

About Voclosporin

Voclosporin, an investigational drug, is a novel and potentially
best-in-class calcineurin inhibitor ("CNI") with clinical data in over
2,200 patients across indications. Voclosporin is an immunosuppressant,
with a synergistic and dual mechanism of action that has the potential
to improve near- and long-term outcomes in LN when added to standard of
care (MMF). By inhibiting calcineurin, voclosporin blocks IL-2
expression and T-cell mediated immune responses. It has been shown to
have a more predictable pharmacokinetic and pharmacodynamic
relationship, an increase in potency, an altered metabolic profile and
potential for flat dosing compared to legacy CNIs. The Company
anticipates that upon regulatory approval, patent protection for
voclosporin will be extended in the United States and certain other
major markets, including Europe and Japan, until at least October 2027
under the Hatch-Waxman Act and comparable laws in other countries.

About Lupus Nephritis (LN)

LN in an inflammation of the kidney caused by Systemic Lupus
Erythematosus ("SLE") and represents a serious progression of SLE. SLE
is a chronic, complex and often disabling disorder and affects more than
500,000 people in the United States (mostly women). The disease is
highly heterogeneous, affecting a wide range of organs & tissue systems.
It is estimated that as many as 60 percent of all SLE patients will
develop clinical LN requiring treatment. Unlike SLE, LN has
straightforward disease outcomes (measuring proteinuria) where an early
response correlates with long-term outcomes. In patients with LN, renal
damage results in proteinuria and/or hematuria and a decrease in renal
function as evidenced by reduced estimated glomerular filtration rate
(eGFR), and increased serum creatinine levels. LN is debilitating and
costly and if poorly controlled, LN can lead to permanent and
irreversible tissue damage within the kidney, resulting in end-stage
renal disease (ESRD), thus making LN a serious and potentially
life-threatening condition.

About Aurinia

Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high unmet
medical need. The company is currently developing voclosporin, an
investigational drug, for the treatment of LN. The company is
headquartered in Victoria, BC and focuses its development efforts
globally. www.auriniapharma.com

Forward Looking Statements

This press release contains forward-looking statements, including
statements related to Aurinia's ability to execute a successful Phase
III program and voclosporin's potential differentiation from its
therapeutic class, Aurinia's analysis, assessment and conclusions of the
results of the AURA-LV clinical study and timing of voclosporin's patent
protection. It is possible that such results or conclusions may change
based on further analyses of these data. Words such as "plans,"
"intends," "may," "will," "believe," and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Aurinia's current expectations.
Forward-looking statements involve risks and uncertainties. Aurinia's
actual results and the timing of events could differ materially from
those anticipated in such forward-looking statements as a result of
these risks and uncertainties, which include, without limitation, the
risk that Aurinia's analyses, assessment and conclusions of the results
of the AURA-LV clinical study, the future success of a Phase III study
and the timing of voclosporin's patent protection set forth in this
release may change based on further analyses of such data, and the risk
that Aurinia's clinical studies for voclosporin may not lead to
regulatory approval. These and other risk factors are discussed under
"Risk Factors" and elsewhere in Aurinia's Annual Information Form for
the year ended December 31, 2016 filed with Canadian securities
authorities and available at www.sedar.com
and on Form 40-F with the U.S. Securities Exchange Commission and
available at www.sec.gov,
each as updated by subsequent filings, including filings on Form 6-K.
Aurinia expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Aurinia's expectations with
regard thereto or any change in events, conditions or circumstances on
which any such statements are based, except as required by law.

1Kidney Int. 2011 Apr;79(8):914-20. doi: 10.1038/ki.2010.525.
Epub 2011 Jan 19.

Persistent proteinuria and dyslipidemia increase the risk of progressive
chronic kidney disease in lupus erythematosus.

Reich HN1, Gladman DD, Urowitz MB, Bargman JM, Hladunewich MA, Lou
W, Fan SC, Su J, Herzenberg AM, Cattran DC, Wither
J, Landolt-Marticorena C, Scholey JW, Fortin PR.

View Comments and Join the Discussion!
 

Partner Center